Doubts Over DBV's Future As US FDA Rejects Peanut Allergy Patch
Development Of Viaskin Peanut Not Smooth
The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.
You may also be interested in...
Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.
Since Palforzia likely will be the only peanut allergy drug on market for some time, Nestle announces it will pay about $2.6bn to acquire the 80% of Aimmune it doesn’t own.
Aimmune has secured approval for the first ever peanut allergy treatment, but safety, cost and administration issues could limit the drug's uptake.